ArticleOncoTargets and therapy2017

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction.

Midori Shimada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.